First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

By | August 9, 2022
Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.